Clinical Trials Arena on MSN3d
MacroGenics axes ADC drug following Phase II failure in prostate cancerThe company stated that although it has dropped vobra duo, it remains optimistic about its other candidate MGC026.
MHC-I upregulation by macbecin II in the solid tumors potentiates the effect of active immunotherapy
Macbecin II was identified as a compound that upregulates MHC-I expression, enhancing immune-mediated cancer cell killing. In ...
Mammalian genomes are organized by multi-level folding, yet how this organization contributes to cell type-specific transcription remain unclear. We uncovered that the nuclear protein SATB1 ...
Golden, CO, Feb. 24, 2025 (GLOBE NEWSWIRE) -- Ignite Proteomics LLC, a subsidiary of IMAC Holdings, Inc. (Nasdaq: BACK), today announced the presentation of new data demonstrating that MHC-II protein ...
Ignite Proteomics LLC, a subsidiary of IMAC Holdings, Inc., announced new findings that show MHC-II protein expression is a more reliable predictor of response to pembrolizumab (Keytruda®) than ...
BACK), today announced the presentation of new data demonstrating that MHC-II protein expression is a superior predictor of response to pembrolizumab (Keytruda ®) compared to PD-L1 at the ...
Ignite Proteomics announced the presentation of new data demonstrating that MHC-II protein expression is a superior predictor of response to pembrolizumab compared to PD-L1 at the upcoming ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback